Anticoagulant Therapy

World Thrombosis Day Article: Renal Vein Thrombosis

Click here for a World Thrombosis Day article about Renal Vein Thrombosis. Introduction Renal vein thrombosis is a blood clot that occurs in the veins draining blood from the kidneys. A blood clot in the renal vein will impact kidney function because it slows the flow of blood from the kidney and can reduce the […]

Anticoagulant Therapy

The Value of Offering DOAC Measurements

Obtain this article from your medical library: Swan D, Roberts L, Thachil J. In a nutshell: testing DOAC levels-when, why and what it means? Br J Haematol. 2026. doi: 10.1111/bjh.70313. PMID: 41482473. Abstract Plasma direct oral anticoagulant (DOAC) levels are not routinely required for the majority of patients; however, they may provide valuable information in […]

Anticoagulant Therapy

Cohort Study: Do Anticonvulsants Interfere with DOAC Therapy?

Navigate to this open-access population cohort study of the effects of anticonvulsants when used during DOAC Rx: Carlin S, Holbrook AM, Candeloro M, et al. Association of direct oral anticoagulant-anticonvulsant coprescription with clinical outcomes in older adults: a population-based cohort study. J Thromb Haemost. 2025:S1538-7836(25)00727-5. doi: 10.1016/j.jtha.2025.10.027. PMID: 41207565. Abstract Background: Anticonvulsants vary in their […]

Anticoagulant Therapy

Anticoagulation Forum Archived Webinars

Fifth on our alphabetical Hemostasis Agencies list is the Anticoagulation Forum. The forum offers a lengthy list of archived educational webinars that describe a number of antithrombotic therapy issues. Click here for the forum’s webinar selection.

Anticoagulant Therapy

Andexanet Alfa Withdrawn from the US Market

Thanks for the heads-up from Dr. Paul Riley, who commented on our December 27, 2025, post, Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal. Here is the press release from AstraZeneca announcing the withdrawal of andexanet alfa from the US market.

Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal

Navigate to this open-access article describing andexanet alfa reversal of LMWH: van Haaps TF, Benz AP, Xu L, Middeldorp S, Eikelboom JW, et al. Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin. Res Pract Thromb Haemost. 2025;9:103191. doi: 10.1016/j.rpth.2025.103191. PMID: 41141842; PMCID: PMC12552982. Abstract Background Andexanet alfa (andexanet) is the only approved reversal […]

Anticoagulant Therapy

August 2025 CAP Today: D-dimer Reporting and INR Are Variables That Matter

In follow-up to their July 2025 CAP Today article, A Deep Dive into Key Hemostasis Testing Variables, Drs. Andrew Goodwin and Eric Salazar present external quality improvement data on the PT–INR, D-dimer, and VET in their August 2025 article, D-dimer Reporting and INR Are Variables That Matter. Their article in particular examines the confusion over […]

Anticoagulant Therapy

Diagnostic Equity Case: Varying INR

This question came from a patient to the Diagnostic Equity Service on 12-9-2025: I notice my INR keeps changing even though I take the same warfarin dose. Could this be a lab issue or a metabolism issue? Thank you for what you do. Abby Carroll, MS, MLS (ASCP)cm answered: In most cases, INR variability is […]

Anticoagulant Therapy

Asundexian Anti-XIa Antithrombotic Shows Promise

Select “Bayer’s Asundexian anti XIa antithrombin met primary efficacy and safety endpoints in a landmark phase III OCEANIC-STROKE study for secondary stroke prevention” for their press release presented at ASH 2025.

Anticoagulant Therapy

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 3: DOACs and Warfarin

Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory and Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, as we discuss the pathophysiology of antiphospholipid antibodies and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with APS. Click DOACs […]

Anticoagulant Therapy

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question